Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters
about
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray CrystallographyThe potential for emerging therapeutic options for Clostridium difficile infectionBiochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin ATyphlitis caused by intestinal Serpulina-like bacteria in domestic guinea pigs (Cavia porcellus).Equine hyperimmune serum protects mice against Clostridium difficile spore challengeImmunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumabImmunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and BIdentification of toxemia in patients with Clostridium difficile infection.Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.Recombinant lipoprotein-based vaccine candidates against C. difficile infections.Models for the study of Clostridium difficile infection.A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse moProtective efficacy induced by recombinant Clostridium difficile toxin fragmentsAntibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin AClostridium difficile infection in the twenty-first century.Protection from Clostridium difficile infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice.Colonic immunopathogenesis of Clostridium difficile infections.Vaccines against Clostridium difficile.Antibodies for treatment of Clostridium difficile infection.New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunizationDevelopment and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.Vaccination against Clostridium difficile using toxin fragments: Observations and analysis in animal modelsDevelopment of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B.The ATP-P2X7 Signaling Axis Is an Essential Sentinel for Intracellular Clostridium difficile Pathogen-Induced Inflammasome Activation.
P2860
Q27683753-1E6043EA-4263-46A8-BC71-E8E66A201236Q28082059-8DCCBADD-7408-4ED6-B89F-658B62172A47Q28547242-A06896A8-4754-48A7-9FDC-B4C6A1AD8E12Q33659097-FFC4EAA6-D0DC-495D-8E37-D51CFC17202BQ33865434-EA613A7A-7737-4ED5-BE25-6170EC886F79Q33866797-3FA72865-0204-4792-8C5C-CA1064B40C50Q34000146-56C7ED8C-85AD-484C-B7CC-6D6F2A257460Q34002040-DCA0751F-7D96-4F6B-B6F4-A1DD60FE4025Q34006013-8D8166E9-0214-4410-9D0C-85A3204603E6Q34832263-3261B58B-85F7-470E-8C2D-0825717AA1CDQ34955629-E3E49720-0A4E-4C81-BF06-E14B8F786B0DQ35075772-AA3A18CB-646D-4895-BFA8-1784306CD903Q35465119-22B4F7F9-377B-4FD0-A898-1604F24CE7EDQ35913487-2E9F2C63-6774-4688-85EE-B51961B76CDBQ35923218-0F7B0FF0-2E79-4946-ABEE-9D2FF848784EQ36019356-5D3B8ABF-BC0A-40EC-98CC-AE65E10B9A8EQ36211064-EE45CCA4-8DC7-45FA-8192-72C57275F58BQ36379304-ADAFDEAE-F1AF-4EFD-9F0E-9D7918B56F3FQ36911461-6C5776E4-0919-4F09-90ED-B8ACD2346348Q37036112-2CD791BF-DA26-4E7B-B3D8-2E5C92F3129FQ37204536-45A97F89-7BFA-4258-ABAD-54385E1BC5E7Q37289567-07680717-39BE-40B0-951F-5B89237DB676Q37546363-91190668-04CD-48F2-9585-70F5F735E125Q37712845-3C44A9F4-00CE-4590-98D6-64F454647941Q38196682-473CC458-7E82-4816-BAB5-4BC28783DC81Q38208794-8B2A9126-1C6E-4CEA-9DF0-40130ADAB97DQ39514376-C8518407-ECD6-474E-B657-09C199F2B1C6Q39768691-07A8F55D-92EA-4474-9DEC-85FE7A734EA6Q40233154-FCA909ED-6F7C-4144-BC46-B3BD7796D724Q40899692-C1A1045C-3C12-497A-B889-366A47DB30C1Q41682391-F310BD73-2ED5-46CC-A0FC-DA8989E06396Q52332673-3A2320D5-0F95-4BA7-BD85-3C479BAE1C57
P2860
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Evaluation of formalin-inactiv ...... es of immunization in hamsters
@ast
Evaluation of formalin-inactiv ...... es of immunization in hamsters
@en
type
label
Evaluation of formalin-inactiv ...... es of immunization in hamsters
@ast
Evaluation of formalin-inactiv ...... es of immunization in hamsters
@en
prefLabel
Evaluation of formalin-inactiv ...... es of immunization in hamsters
@ast
Evaluation of formalin-inactiv ...... es of immunization in hamsters
@en
P2093
P2860
P1476
Evaluation of formalin-inactiv ...... es of immunization in hamsters
@en
P2093
P2860
P304
P407
P577
1995-12-01T00:00:00Z